These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2078022)

  • 1. Strategies to inhibit viral polyprotein cleavages.
    Korant BD
    Ann N Y Acad Sci; 1990; 616():252-7. PubMed ID: 2078022
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.
    Sices HJ; Leusink MD; Pacheco A; Kristie TM
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1249-55. PubMed ID: 11559424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
    Gallego O; Corral A; de Mendoza C; Soriano V
    Clin Infect Dis; 2002 May; 34(9):1288-9. PubMed ID: 11941567
    [No Abstract]   [Full Text] [Related]  

  • 5. A drug discovery platform: a simplified immunoassay for analyzing HIV protease activity.
    Kitidee K; Nangola S; Hadpech S; Laopajon W; Kasinrerk W; Tayapiwatana C
    J Virol Methods; 2012 Dec; 186(1-2):21-9. PubMed ID: 22846787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 protease cleaves actin during acute infection of human T-lymphocytes.
    Adams LD; Tomasselli AG; Robbins P; Moss B; Heinrikson RL
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):291-5. PubMed ID: 1540415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
    Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
    Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIVdb: a database of the structures of human immunodeficiency virus protease.
    Vondrasek J; Wlodawer A
    Proteins; 2002 Dec; 49(4):429-31. PubMed ID: 12402352
    [No Abstract]   [Full Text] [Related]  

  • 9. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.
    Karacostas V; Wolffe EJ; Nagashima K; Gonda MA; Moss B
    Virology; 1993 Apr; 193(2):661-71. PubMed ID: 7681610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism.
    Pettit SC; Everitt LE; Choudhury S; Dunn BM; Kaplan AH
    J Virol; 2004 Aug; 78(16):8477-85. PubMed ID: 15280456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active human immunodeficiency virus protease is required for viral infectivity.
    Kohl NE; Emini EA; Schleif WA; Davis LJ; Heimbach JC; Dixon RA; Scolnick EM; Sigal IS
    Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4686-90. PubMed ID: 3290901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro.
    McPhee F; Caldera PS; Bemis GW; McDonagh AF; Kuntz ID; Craik CS
    Biochem J; 1996 Dec; 320 ( Pt 2)(Pt 2):681-6. PubMed ID: 8973584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
    Krauchenco S; Martins NH; Sanches M; Polikarpov I
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):638-45. PubMed ID: 18825538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly resistant HIV-1 proteases and strategies for their inhibition.
    Weber IT; Kneller DW; Wong-Sam A
    Future Med Chem; 2015; 7(8):1023-38. PubMed ID: 26062399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation in vitro and in mammalian cells of new heteroaryl carboxyamides as HIV-protease inhibitors.
    Funicello M; Chiummiento L; Tramutola F; Armentano MF; Bisaccia F; Miglionico R; Milella L; Benedetti F; Berti F; Lupattelli P
    Bioorg Med Chem; 2017 Sep; 25(17):4715-4722. PubMed ID: 28739156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
    Lu Z; Bohn J; Rano T; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5311-4. PubMed ID: 16203148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoprocessing of HIV-1 protease is tightly coupled to protein folding.
    Louis JM; Clore GM; Gronenborn AM
    Nat Struct Biol; 1999 Sep; 6(9):868-75. PubMed ID: 10467100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interview with Celia Schiffer.
    Schiffer C
    Future Med Chem; 2013 Jul; 5(11):1193-7. PubMed ID: 23859201
    [No Abstract]   [Full Text] [Related]  

  • 20. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.